Neuroimmune Tau Mechanisms: Their Role in the Progression of Neuronal Degeneration
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Progressive neurodegenerative pathologies in aged populations are an issue of major concern worldwide. The microtubule-associated protein tau is able to self-aggregate to form abnormal supramolecular structures that include small oligomers up to complex polymers. Tauopathies correspond to a group of diseases that share tau pathology as a common etiological agent. Since microglial cells play a preponderant role in innate immunity and are the main source of proinflammatory factors in the central nervous system (CNS), the alterations in the cross-talks between microglia and neuronal cells are the main focus of studies concerning the origins of tauopathies. According to evidence from a series of studies, these changes generate a feedback mechanism reactivating microglia and provoking constant cellular damage. Thus, the previously summarized mechanisms could explain the onset and progression of different tauopathies and their functional/behavioral effects, opening the window towards an understanding of the molecular basis of anomalous tau interactions. Despite clinical and pathological differences, increasing experimental evidence indicates an overlap between tauopathies and synucleinopathies, considering that neuroinflammatory events are involved and the existence of protein misfolding. Neurofibrillary tangles of pathological tau (NFT) and Lewy bodies appear to coexist in certain brain areas. Thus, the co-occurrence of synucleinopathies with tauopathies is evidenced by several investigations, in which NFT were found in the substantia nigra of patients with Parkinson’s disease, suggesting that the pathologies share some common features at the level of neuroinflammatory events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tau in physiology and pathology
Wang, Y., & Mandelkow, E. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.1 · Cited by 2,251 · cited 4×
“Furthermore, other alterations in FTD categorized as “related FTD” include: motoneuron disorders FTD (MNFTD), progressive supranuclear palsy (PSP-FTD), and corticobasal syndromes (CBS) [37,45].”
BackgroundInfluentialSynapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.010 · Cited by 2,208
Goedert, M., Jakes, R., Spillantini, M. G., Hasegawa, M., Smith, M. J., & Crowther, R. A. (1996) · Nature · doi:10.1038/383550a0 · Cited by 1,036 · cited 1×
“In this perspective, a major difference between tau and α-syn is that α-syn is prone to self-aggregate, whereas tau cannot aggregate by itself and requires an inducing agent [96].”
BackgroundMackenzie, I. R. A., Neumann, M., Bigio, E. H., Cairns, N. J., Alafuzoff, I., Kril, J., Kovacs, G. G., Ghetti, B., Halliday, G., Holm, I. E., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0612-2 · Cited by 1,012 · cited 3×
“Finally, there is another distinction based on the neuropathological alterations that affect mainly the frontal and temporal lobes, named “frontotemporal lobar degeneration” (FTLD), where specific protein aggregates determine different types of FTD termed: FTLD-tau (tau protein), FTLD-TDP (transactive response of DNA-…”
BackgroundCleveland, D. W., Hwo, S.-Y., & Kirschner, M. W. (1977) · Journal of Molecular Biology · doi:10.1016/0022-2836(77)90213-3 · Cited by 915 · cited 2×
“Mark Kirschne ’s group in October 1977 was the first to describe a protein, named as tau, th Greek letter to differentiate from tubulin [7].”
BackgroundInitiation and Synergistic Fibrillization of Tau and Alpha-Synuclein
Giasson, B. I., Forman, M. S., Higuchi, M., Golbe, L. I., Graves, C. L., Kotzbauer, P. T., Trojanowski, J. Q., & Lee, V. M.-Y. (2003) · Science · doi:10.1126/science.1082324 · Cited by 879
Thomas, B., & Beal, M. F. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm159 · Cited by 748
Tau protein kinases: Involvement in Alzheimer's disease
Martin, L., Latypova, X., Wilson, C. M., Magnaudeix, A., Perrin, M.-L., Yardin, C., & Terro, F. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2012.06.003 · Cited by 631 · cited 1×
“This kinase has three isoforms that participate in brain development, immune modulation, induction of LTP, neurite formation, and JNK3, in particular, induces cell death by apoptosis [15].”
BackgroundThe epidemiology of frontotemporal dementia
Onyike, C. U., & Diehl-Schmid, J. (2013) · International Review of Psychiatry · doi:10.3109/09540261.2013.776523 · Cited by 543
Morales, I., Guzmán-MartÃnez, L., Cerda-Troncoso, C., FarÃas, G. A., & Maccioni, R. B. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00112 · Cited by 490 · cited 2×
“This leads to an increase in the expression of the CDK5/p35 (cyclin-dependent kinase 5) complex, GSK3-β (glycogen synthase kinase 3-β), tau hyperphosphorylation, and the subsequent self-aggregation linked with neuronal degeneration [12].”
BackgroundSelf-citationThe molecular bases of Alzheimer’s disease and other neurodegenerative disorders
Maccioni, R. B., Muñoz, J. P., & Barbeito, L. (2001) · Archives of Medical Research · doi:10.1016/s0188-4409(01)00316-2 · Cited by 474
Tau association with synaptic vesicles causes presynaptic dysfunction
Zhou, L., McInnes, J., Wierda, K., Holt, M., Herrmann, A. G., Jackson, R. J., Wang, Y.-C., Swerts, J., Beyens, J., Miskiewicz, K., et al. (2017) · Nature Communications · doi:10.1038/ncomms15295 · Cited by 434 · cited 2×
“Moreover, tau is implicated in more than 20 neurodegenerative diseases [23], and therefore, it is of interest to review at least some of them.”
BackgroundOlney, N. T., Spina, S., & Miller, B. L. (2017) · Neurologic Clinics · doi:10.1016/j.ncl.2017.01.008 · Cited by 419
Jensen, P. H., Hager, H., Nielsen, M. S., Højrup, P., Gliemann, J., & Jakes, R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.36.25481 · Cited by 377 · cited 4×
“In vitro studies have shown binding of α-syn to tau, inducing their phosphorylations [84].”
BackgroundInfluentialNeuroinflammation: Implications for the Pathogenesis and Molecular Diagnosis of Alzheimer's Disease
Rojo, L. E., Fernández, J. A., Maccioni, A. A., Jimenez, J. M., & Maccioni, R. B. (2008) · Archives of Medical Research · doi:10.1016/j.arcmed.2007.10.001 · Cited by 351 · cited 1×
“Additionally, synaptic loss and microgliosis was observed before the NFT formation in the hippocampus of a transgenic mouse with the human tau mutation associated with the FTD model, thus, determining that inflammation can lead to NFT formation in FTD tauopathies [31], in agreement with our neuroimmunomodulation theor…”
ResultSelf-citationThe genetics and neuropathology of frontotemporal lobar degeneration
Sieben, A., Van Langenhove, T., Engelborghs, S., Martin, J.-J., Boon, P., Cras, P., De Deyn, P.-P., Santens, P., Van Broeckhoven, C., & Cruts, M. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1029-x · Cited by 280 · cited 1×
“These groupings are not mutually exclusive, and we will focus here on the FTD caused by tau inclusions (FTD-tauopathies), which encompass around half of the total FTDs and are characterised by the presence of tau aggregates in neuronal and/or glial cells [48].”
BackgroundEstimating the Number of Persons with Frontotemporal Lobar Degeneration in the US Population
Knopman, D. S., & Roberts, R. O. (2011) · Journal of Molecular Neuroscience · doi:10.1007/s12031-011-9538-y · Cited by 236 · cited 1×
“FTD is the second most important “dementia” after AD, in terms of the number of people that suffer from the disease [38,39].”
BackgroundImaging and fluid biomarkers in frontotemporal dementia
Meeter, L. H., Kaat, L. D., Rohrer, J. D., & van Swieten, J. C. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.75 · Cited by 210 · cited 1×
“Additionally, cerebrospinal fluid (CSF) biomarkers established by the specific ratio between total levels of tau and Aβ1–42, and phosphorylated tau and Aβ1–42 has been described as a robust discriminator between FTD and AD [53,54].”
BackgroundTau-Centric targets and drugs in clinical development for the treatment of alzheimer's disease
Panza, F., Solfrizzi, V., Seripa, D., Imbimbo, B. P., Lozupone, M., Santamato, A., Zecca, C., Barulli, M. R., Bellomo, A., Pilotto, A., et al. (2016) · BioMed Research International · doi:10.1155/2016/3245935 · Cited by 195
In vivo detection of microglial activation in frontotemporal dementia
Cagnin, A., Rossor, M., Sampson, E. L., MacKinnon, T., & Banati, R. B. (2004) · Annals of Neurology · doi:10.1002/ana.20332 · Cited by 187
Arai, Y., Yamazaki, M., Mori, O., Muramatsu, H., Asano, G., & Katayama, Y. (2001) · Brain Research · doi:10.1016/s0006-8993(00)03082-1 · Cited by 173
Neuroimmunomodulation in the Pathogenesis of Alzheimer’s Disease
Morales, I., Farías, G., & Maccioni, R. B. (2010) · Neuroimmunomodulation · doi:10.1159/000258724 · Cited by 162
Self-citationTau Oligomers and Fibrils Induce Activation of Microglial Cells
Morales, I., Jiménez, J. M., Mancilla, M., & Maccioni, R. B. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-131843 · Cited by 160 · cited 3×
“Increasin evidence sug ests th t tau oligomers an polymers eleased up n neuronal apoptosis are capable of reactivating microglial cells, thus, favoring the continuous cascad of altered molecular gnaling responsibl for neuronal degeneration in tauopathies and AD [14].”
BackgroundInfluentialSelf-citationSjogren, M. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.019422 · Cited by 125
PET Imaging of Neuropathology in Tauopathies: Progressive Supranuclear Palsy
Kepe, V., Bordelon, Y., Boxer, A., Huang, S.-C., Liu, J., Thiede, F. C., Mazziotta, J. C., Mendez, M. F., Donoghue, N., Small, G. W., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130032 · Cited by 106 · cited 1×
“They also showed the presence of hyperphosphorylated tau in several regions, some previously related to consciousness, such as the striatum, thalamus, subthalamic region, midbrain, and cerebellar white matter [26].”
BackgroundImproving response inhibition systems in frontotemporal dementia with citalopram
Hughes, L. E., Rittman, T., Regenthal, R., Robbins, T. W., & Rowe, J. B. (2015) · Brain · doi:10.1093/brain/awv133 · Cited by 100 · cited 2×
“FTD is the second most important “dementia” after AD, in terms of the number of people that suffer from the disease [38,39].”
BackgroundGolde, T. E., & Miller, V. M. (2009) · Alzheimer's Research & Therapy · doi:10.1186/alzrt5 · Cited by 98 · cited 1×
“This misfolding and oligomerization of α-syn is called synucleinopathy [65,66].”
BackgroundTau imaging with [18F]THK‐5351 in progressive supranuclear palsy
Ishiki, A., Harada, R., Okamura, N., Tomita, N., Rowe, C. C., Villemagne, V. L., Yanai, K., Kudo, Y., Arai, H., Furumoto, S., et al. (2017) · European Journal of Neurology · doi:10.1111/ene.13164 · Cited by 92
Stimulatory effect of α‐synuclein on the tau‐phosphorylation by GSK‐3 β
Kawakami, F., Suzuki, M., Shimada, N., Kagiya, G., Ohta, E., Tamura, K., Maruyama, H., & Ichikawa, T. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2011.08389.x · Cited by 82
Mapping neuroinflammation in frontotemporal dementia with molecular PET imaging
Zhang, J. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0236-5 · Cited by 62
[18F]AV‐1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation
Bevan Jones, W. R., Cope, T. E., Passamonti, L., Fryer, T. D., Hong, Y. T., Aigbirhio, F., Kril, J. J., Forrest, S. L., Allinson, K., Coles, J. P., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.366 · Cited by 44
Cited by
Neuroinflammation as a common feature of neurodegenerative disorders
Guzman-Martinez, L., Maccioni, R. B., Andrade, V., Navarrete, L. P., Pastor, M. G., & Ramos-Escobar, N. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01008 · Cited by 702
Self-citationAlzheimer’s Disease: An Updated Overview of Its Genetics
Andrade-Guerrero, J., Santiago-Balmaseda, A., Jeronimo-Aguilar, P., Vargas-Rodríguez, I., Cadena-Suárez, A. R., Sánchez-Garibay, C., Pozo-Molina, G., Méndez-Catalá, C. F., Cardenas-Aguayo, M.-D.-C., Diaz-Cintra, S., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043754 · Cited by 336
The Microbiota–Gut–Brain Axis and Alzheimer’s Disease: Neuroinflammation Is to Blame?
Megur, A., Baltriukienė, D., Bukelskienė, V., & Burokas, A. (2020) · Nutrients · doi:10.3390/nu13010037 · Cited by 323
“NFTs formed inside the neuron disrupt the microtubule structure and form an insoluble substance, which is detected in the locus coeruleus, and transentorhinal and entorhinal areas of the brain [35].”
BackgroundInnate Immune Cell Death in Neuroinflammation and Alzheimer’s Disease
Rajesh, Y., & Kanneganti, T.-D. (2022) · Cells · doi:10.3390/cells11121885 · Cited by 262
Reich, N., & Hölscher, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.970925 · Cited by 248
Metadata
- Authors
- Cortés, N., Andrade, V., Guzmán-Martínez, L., Estrella, M., & Maccioni, R.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2018-03-23
- Volume
- 19
- Issue
- 4
- Pages
- 956
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2790975021
- Cited by
- 42
- References
- 31
- FWCI
- 2.38
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.